M. Bilal Abid, Medical Director, Blood and Marrow Transplantation and Cellular Therapy Program at Texas Tech University Health Sciences Center, shared on LinkedIn:
“Hot off the press
Phase II Griffin and phase III PERSEUS studies established the role of quadruplet D-VRd induction followed by autologous hematopoietic cell transplantation (autoHCT) and Len maintenance.
However, clinical trial and patients in our clinics are different and real world data remain limited.
We conducted a study at the University of Texas MD Anderson Cancer Center that included patients with NDMM who received D-VRd induction, upfront autoHCT followed by single-agent Len maintenance.
Response and progression were defined according to the International Myeloma Working Group (IMWG) criteria.
High-risk cytogenetic abnormalities were defined as del17p, t(4;14), t(14;16), or 1q21 gain or amplification by FISH. Patients were also risk stratified using the 2025 International Myeloma Society (IMS)/IMWG classification to identify high-risk patients.
Results:
- In this real-world study of patients with NDMM, treated with contemporary SOC D-VRd induction, autoHCT and Len maintenance, we demonstrated CR and MRD negativity rates of 72% and 71%, respectively, and a 2-year PFS of 88%.
- Patients classified as having high-risk disease according to the 2025 IMS/IMWG criteria had inferior outcomes, with a 2-year PFS of 77%.
Key Takeaway:
- Quadruplet induction is the standard of care in multiple myeloma.
- Real world analyses results are in congruence with trial level data.
- Although encouraging overall, these results highlight the continued need for more effective strategies for patients with high-risk disease, including anti-CD38 antibody-based doublet maintenance, or the incorporation of BCMA-directed therapies in earlier lines.
Greatly appreciate collaborators, mentors, mentees, patients and families for contributing data!”
Title: Daratumumab, Bortezomib, Lenalidomide and Dexamethasone, Upfront Autologous Transplant and Lenalidomide Maintenance for Newly Diagnosed Multiple Myeloma
Authors: Oren Pasvolsky, Muhammad Bilal Abid, Denái R. Milton, Mark R. Tanner, Sohaib Irfan, Qaiser Bashir, Samer Srour, Neeraj Saini, Paul Lin, Jeremy Ramdial, Yago Nieto, Guilin Tang, Asad A. Haider, Yosra Aljawai, Partow Kebriaei, Krina K. Patel, Christine Ye, Sheeba K. Thomas, Robert Z. Orlowski, Richard E. Champlin, Elizabeth J. Shpall, Muzaffar H. Qazilbash
You can also read: FDA Grants Accelerated Approval to Bristol Myers Squibb’s Zenbexus Plus Daratumumab and Hyaluronidase-fihj and Dexamethasone for Multiple Myeloma.
